Study to Define the Electrocardiogram Effects of a Single Dose of LX4211 in Healthy Subjects
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This Phase 1 study is to investigate the effects of higher doses of LX4211 (800 mg and 2000
mg) do not differ from placebo in the mean change in QTcI from Baseline in healthy subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Lexicon Pharmaceuticals
Treatments:
(2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol Fluoroquinolones Moxifloxacin Norgestimate, ethinyl estradiol drug combination